New FDA Draft Guidance Shows That the Time for Decentralized Clinical Trials is Now.


Sponsored Content

On May 1, 2023, the U.S. Food and Drug Administration (FDA) released an updated Draft Guidance on decentralized trials. This release shows that the landscape of clinical research is rapidly evolving. The shift towards decentralized clinical trials presents an exciting opportunity for sponsors to improve patient engagement, enhance data quality, and accelerate clinical research. Are you prepared for what’s to come? Download the insight brief to learn more.

Related Content
© 2024 MJH Life Sciences

All rights reserved.